Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.
Sugawara S, Maemondo M, Tachihara M, Inoue A, Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T; North Japan Lung Cancer Study Group. Sugawara S, et al. Among authors: watanabe h, watanabe k. Lung Cancer. 2013 Jul;81(1):91-6. doi: 10.1016/j.lungcan.2013.04.010. Epub 2013 May 1. Lung Cancer. 2013. PMID: 23643176 Clinical Trial.
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T. Maemondo M, et al. Among authors: watanabe k. Oncologist. 2014 Apr;19(4):352-3. doi: 10.1634/theoncologist.2013-0411. Epub 2014 Mar 28. Oncologist. 2014. PMID: 24682465 Free PMC article. Clinical Trial.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R. Okada K, et al. Among authors: watanabe k. EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17. EBioMedicine. 2019. PMID: 30662002 Free PMC article.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: watanabe s, watanabe k. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M. Tsukita Y, et al. Among authors: watanabe k. Lung Cancer. 2020 Jan;139:89-93. doi: 10.1016/j.lungcan.2019.10.016. Epub 2019 Oct 18. Lung Cancer. 2020. PMID: 31751805 Clinical Trial.
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada PM, Yoshimori K, Nakachi I, Gemma PA, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara PK, Nukiwa PT, Morita PS, Kobayashi PK, Maemondo PM. Fukuhara T, et al. Among authors: watanabe s, watanabe k. EBioMedicine. 2020 Jul;57:102861. doi: 10.1016/j.ebiom.2020.102861. Epub 2020 Jul 3. EBioMedicine. 2020. PMID: 32629391 Free PMC article. Clinical Trial.
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001.
Watanabe K, Toi Y, Nakamura A, Chiba R, Akiyama M, Sakakibara-Konishi J, Tanaka H, Yoshimura N, Miyauchi E, Nakagawa T, Igusa R, Minemura H, Mori Y, Fujimoto K, Matsushita H, Takahashi F, Fukuhara T, Inoue A, Sugawara S, Maemondo M; North Japan Lung Cancer Study Group, Sendai, Japan. Watanabe K, et al. Transl Lung Cancer Res. 2021 Feb;10(2):712-722. doi: 10.21037/tlcr-20-721. Transl Lung Cancer Res. 2021. PMID: 33718016 Free PMC article.
15,955 results
You have reached the last available page of results. Please see the User Guide for more information.